Anastrozole therapy for postmenopausal women with early breast cancer

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res. Treat.76(1), 27–36 (2002).
   PubMed Web of Science ®Google Scholar
• Huober J, Krainick-Strobel U, Kurek R, Wallwiener D. Neoadjuvant endocrine therapy in primary breast cancer. Clin. Breast Cancer5(5), 341–347 (2004).
   PubMedGoogle Scholar
• Tondini C, Fenaroli P, Labianca R. Preoperative endocrine therapy for postmenopausal women: when and why? Ann. Oncol.12, 1505–1506 (2001).
   PubMedGoogle Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet351(9114), 1451–1467 (1998).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet352(9132), 930–942 (1998).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann. Oncol.16(10), 1569–1583 (2005).
   PubMed Web of Science ®Google Scholar
• Forbes JF. Choosing between endocrine therapy and chemotherapy – or is there a role for combination therapy? Breast Cancer Res. Treat.75, S45–S50 (2002).
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst. Rev.1 (2004).
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365(9472), 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl Cancer Inst.86(7), 527–537 (1994).
   PubMed Web of Science ®Google Scholar
• Cutuli B, Petit JC, Fricker JP et al. Adjuvant tamoxifen in breast cancer treatment in postmenopausal women: occurrence of thromboembolic complications. Oncol. Rep.1, 59–63 (1994).
   PubMedGoogle Scholar
• Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat. Res.591(1–2), 247–263 (2005).
   PubMed Web of Science ®Google Scholar
• Esteban JM, Warsi Z, Haniu M, Hall P, Shively JE, Chen S. Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. Am. J. Pathol.140(2), 337–343 (1992).
   PubMedGoogle Scholar
• Miller WR. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr. Relat. Cancer6(2), 187–195 (1999).
   PubMed Web of Science ®Google Scholar
• Buzdar AU. Aromatase inhibitors: changing the face of endocrine therapy for breast cancer. Breast Dis.24, 107–117 (2005).
   PubMedGoogle Scholar
• Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer: status report 2004. J. Clin. Oncol.23(3), 619–629 (2005).
   PubMed Web of Science ®Google Scholar
• Samojlik E, Veldhuis JD, Wells SA, Santen RJ. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. J. Clin. Invest.65(3), 602–612 (1980).
   PubMed Web of Science ®Google Scholar
• Kardinal CG, Donegan WL. Cancer of the breast. Endocrine and hormonal therapy. Major Probl. Clin. Surg.5, 361–404 (1979).
   PubMedGoogle Scholar
• Cohen IA, Keller JH, Abate MA. Management of breast cancer. Clin. Pharm.1(6), 515–529 (1982).
   PubMedGoogle Scholar
• Perez N, Borja J. Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer. J. Int. Med. Res.20(4), 303–312 (1992).
   PubMed Web of Science ®Google Scholar
• Wiseman LR, McTavish D. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer. Drugs45(1), 66–84 (1993).
   PubMed Web of Science ®Google Scholar
• Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol.20(3), 751–757 (2002).
   PubMed Web of Science ®Google Scholar
• Harris AL, Dowsett M, Cantwell BM et al. Endocrine effects of low dose aminoglutethimide with hydrocortisone – an optimal hormone suppressive regimen. Breast Cancer Res. Treat.7(Suppl.), S69–S72 (1986).
   Google Scholar
• Buzdar AU, Jonat W, Howell A et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer83(6), 1142–1152 (1998).
   PubMed Web of Science ®Google Scholar
• Geisler J, King N, Dowsett M et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br. J. Cancer74(8), 1286–1291 (1996).
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J. Clin. Oncol.18(22), 3758–3767 (2000).
   PubMed Web of Science ®Google Scholar
• ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet365(9451), 60–62 (2005).
   PubMed Web of Science ®Google Scholar
• Harvey HA. Aromatase inhibitors in clinical practice: current status and a look to the future. Semin. Oncol.23(4 Suppl. 9), 33–38 (1996).
   PubMedGoogle Scholar
• Plourde PV, Dyroff M, Dowsett M, Demers L, Yates R, Webster A. Arimidex™: a new oral, once-a-day aromatase inhibitor. J. Steroid Biochem. Mol. Biol.53, 175–179 (1995).
   PubMed Web of Science ®Google Scholar
• Yates RA, Dowsett M, Fisher GV, Selen A, Wyld PJ. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br. J. Cancer73(4), 543–548 (1996).
   PubMed Web of Science ®Google Scholar
• Buzdar A, Robertson JFR, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer95(9), 2006–2016 (2002).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Vorobiof DA, Kleeberg I et al. A randomised study assessing oestrogen suppression with ‘Arimidex’ (anastrozole) and formestane in postmenopausal advanced breast cancer (ABC) patients. Eur. J. Cancer32A(Suppl. 2), 49 (1996).
   Google Scholar
• Dowsett M, Yates R, Wong Y et al. ‘Arimidex’ (anastrozole): lack of interactions with tamoxifen, antipyrine, cimetidine and warfarin. Eur. J. Cancer34(S39), 100 (1998).
   Google Scholar
• Yates RA, Wong J, Seiberling M, Merz M, Marz W, Nauck M. The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br. J. Clin. Pharmacol.51(5), 429–435 (2001).
   PubMed Web of Science ®Google Scholar
• Dukes M, Edwards PN, Large M, Smith IK, Boyle T. The preclinical pharmacology of “Arimidex” (anastrozole; ZD1033) – a potent, selective aromatase inhibitor. J. Steroid. Biochem. Mol. Biol.58(4), 439–445 (1996).
   PubMed Web of Science ®Google Scholar
• Esparza-Guerra L, Buzdar A. Anastrozole ‘Arimidex’ does not impair adrenal cortisol or aldosterone synthesis in postmenopausal women with advanced breast cancer. Proc. Am. Soc. Clin. Oncol.20(53b), 1954 (2001).
   Google Scholar
• Grimm SW, Dyroff MC. Inhibition of human drug metabolizing cytochromes p450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab. Dispos.25(5), 598–602 (1997).
   PubMed Web of Science ®Google Scholar
• Plourde PV, Dyroff M, Dukes M. Arimidex®: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res. Treat.30(1), 103–111 (1994).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Donaldson K, Tsuboi M, Wong J, Yates R. Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women. Cancer Chemother. Pharmacol.46(1), 35–39 (2000).
   PubMed Web of Science ®Google Scholar
• Vorobiof DA, Kleeberg UR, Perez-Carrion R et al. A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex®) with intramuscular formestane in postmenopausal women with advanced breast cancer. Ann. Oncol.10(10), 1219–1225 (1999).
   PubMed Web of Science ®Google Scholar
• Geisler J, Detre S, Berntsen H et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin. Cancer Res.7(5), 1230–1236 (2001).
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Guglielmini P et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann. Oncol.17(Suppl. 7), vii10–vii14 (2006).
   PubMed Web of Science ®Google Scholar
• Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet366(9484), 455–462 (2005).
   PubMed Web of Science ®Google Scholar
• Jonat W, Gnant M, Boccardo F et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol.7(12), 991–996 (2006).
   PubMed Web of Science ®Google Scholar
• Jakesz R, Samonigg H, Greil R et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J. Clin. Oncol. (Meeting Abstracts)23(16s part I of II), 10s, abs 527 (2005).
   Web of Science ®Google Scholar
• Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol.23(22), 5108–5116 (2005).
   PubMed Web of Science ®Google Scholar
• Cataliotti L, Buzdar AU, Noguchi S et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative “Arimidex” compared to Tamoxifen (PROACT) trial. Cancer106(10), 2095–2103 (2006).
   PubMed Web of Science ®Google Scholar
• The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet359(9324), 2131–2139 (2002).
   PubMed Web of Science ®Google Scholar
• The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer98(9), 1802–1810 (2003).
   PubMed Web of Science ®Google Scholar
• Cuzick J. Aromatase inhibitors in prevention – data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res.163, 96–103 (2003).
   PubMedGoogle Scholar
• Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl Cancer Inst.93(9), 684–690 (2001).
   PubMed Web of Science ®Google Scholar
• The ATAC Trialists’ Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol.7(8), 633–643 (2006).
   PubMed Web of Science ®Google Scholar
• Bissett D, Davis JA, George WD. Gynaecological monitoring during tamoxifen therapy. Lancet344(8932), 1244 (1994).
   PubMedGoogle Scholar
• Coombes RC, Hall E, Snowdon CF, Bliss JM, on behalf of the Intergroup Exemestane Study (IES). The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen - updated survival analysis. Breast Cancer Res. Treat.88(Suppl. 1), S7, abs 3 (2004).
   Google Scholar
• Thürlimann B, Kesaviah A, Mouridsen H et al. BIG 1–98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. J. Clin. Oncol. (Meeting Abstracts)23(6s), 511 (2005).
   Google Scholar
• Eastell R, Hannon R. Long-term effects of aromatase inhibitors on bone. J. Steroid. Biochem. Mol. Biol.95(1–5), 151–154 (2005).
   PubMed Web of Science ®Google Scholar
• Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J. Bone Miner. Res.21(8), 1215–1223 (2006).
   PubMed Web of Science ®Google Scholar
• Eastell R, Hannon RA, Cuzick J, Clack G, Adams J. Effect of anastrozole on bone mineral density: 5-year results of the ‘Arimidex’ (anastrozole), tamoxifen, alone or in combination (ATAC) trial. Calcif. Tissue Int.78(Suppl. 1), S25 (2006).
   PubMed Web of Science ®Google Scholar
• McCloskey E, Hannon R, Lakner G, Clack G, Miyamoto A, Eastell R. The letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial: a direct comparison of bone biochemical measurements between aromatase inhibitors (AIs) in healthy postmenopausal women. J. Clin. Oncol. (Meeting Abstracts)24(18S), 555 (2006).
   Google Scholar
• McCloskey E, Hannon R, Lakner G et al. Complete data from the letrozole, exemestane, and anastrozole pharmacodynamics ‘LEAP’ trial: direct comparison of safety parameters between aromatase inhibitors in healthy. Proceedings of the San Antonio Breast Cancer Symposium, TX, USA, 14–17 December (2006).
   Google Scholar
• Van Poznack C, Hannon RA, Clack G et al. The SABRE study: effects of risedronate on bone mineral density and bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone receptor-positive early breast cancer – first results. Proceedings of the San Antonio Breast Cancer Symposium, TX, USA, 14–17 December (2006).
   Google Scholar
• Bonneterre J, Thürlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J. Clin. Oncol.18(22), 3748–3757 (2000).
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Bonneterre J, Buzdar A, Robertson JFR, Thürlimann B, for the Arimidex Writing Committee on behalf of the Investigators. Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur. J. Cancer39(12), 1684–1689 (2003).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN practice guidelines in oncology v.2.2006: breast cancer. (2006).
   Google Scholar
• Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J. Gen. Intern. Med.18(11), 937–947 (2003).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet361(9354), 296–300 (2003).
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Honig S, Beitz J. Uterine sarcoma associated with tamoxifen use. N. Engl. J. Med.346(23), 1832–1833 (2002).
   PubMed Web of Science ®Google Scholar
• Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of Study BIG 1–98. J. Clin. Oncol.25(5), 486–492 (2007).
   PubMed Web of Science ®Google Scholar
• Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet369(9561), 559–570 (2007).
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Gligorov J. Cardiovascular safety profiles of aromatase inhibitors: a comparative review. Drug Saf.29(9), 785–801 (2006).
   PubMedGoogle Scholar
• Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst.97(17), 1262–1271 (2005).
   PubMed Web of Science ®Google Scholar
• Elisaf MS, Bairaktari ET, Nicolaides C et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur. J. Cancer37(12), 1510–1513 (2001).
   PubMed Web of Science ®Google Scholar
• Wasan KM, Goss PE, Pritchard PH et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann. Oncol.16(5), 707–715 (2005).
   PubMed Web of Science ®Google Scholar
• Wojtacki J, Lesniewski-Kmak K, Piotrowska M, Rolka-Stempniewicz G, Kubik M, Wroblewska M. Effect of anastrozole on serum levels of apolipoprotein A-I and B in patients with early breast cancer: additional data on lack of atherogenic properties. Breast Cancer Res. Treat.88(S238), 6053 (2004).
   Google Scholar
• Wojtacki J, Lesniewski-Kmak K, Pawlak W, Nowicka E. Anastrozole therapy and lipid profile: an update. Eur. J. Cancer Suppl.2(3), 142 (2004).
   Web of Science ®Google Scholar
• McCloskey E, Eastell R, Lakner G, Miyamoto A, Clack G. Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Breast Cancer Res. Treat.94(S101), 2052 (2005).
   Google Scholar
• NCT00022672. A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer. (2006).
   Google Scholar
• Mackey JR, Kaufman B, Clemens M et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res. Treat.100(Suppl. 1), S5 (2006).
   Google Scholar
• Dowsett M, Smith I, Skene A et al. Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenopausal women with ER/PgR+ breast cancer (Study 223). J. Clin. Oncol. (Meeting Abstracts)24(18 Suppl.), 515 (2006).
   Google Scholar